Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin backgroundJ.G. Robinson,M. Farnier,J.J. Kastelein, E.M. Roth,M.R. Taskinen, H.M. Colhoun, A. Brunet, A.T. DiCioccio, G. Lecorps,R. Pordy,M.T. Baccara-Dinet,C.P. CannonAtherosclerosis（2016）引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
